Defitelio (defibrotide): Do not use for prophylaxis of veno- occlusive disease (VOD) after post-hematopoietic stem-cell transplantation (HSCT).

Summary:

• Study 15-007 comparing defibrotide plus best supportive care (BSC) with BSC as prophylaxis of VOD after HSCT was stopped due to futility.
• No effect on the primary efficacy endpoint of VOD-free survival by day +30 post-HSCT was seen.
• Defitelio is not to be used as prophylaxis for VOD.